For example, itaconate, which is primarily imported from tumor‐associated macrophages via SLC13A3, can activate the NRF2‐SLC7A11 pathway, thereby enabling tumor cells to escape from ferroptosis and promoting resistance to immune checkpoint blockade.[39] Therefore, further studies are warranted to investigate whether PIP5K1A regulates ferroptosis resistance through TME modulation, and if combining PIP5K1A knockdown with first‐line immunotherapy could improve therapeutic outcomes in HCC. Here, SLC7A11 is linked to neoplasm.